ストックスクリーナーアプリを入手
25.61
6.46%
-1.8097
前日終値:
$27.42
開ける：
$27.48
24時間の取引高:
1.21M
Relative Volume:
0.86
時価総額：
$2.67B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-14.15
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
-5.87%
1か月 パフォーマンス:
-10.35%
6か月 パフォーマンス:
-2.47%
1年 パフォーマンス:
-31.36%
1日の値動き範囲:
$24.70
$28.34
1週間の範囲:
$24.03
$29.05
52週間の値動き範囲:
$20.84
$37.42
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
25.61 | 2.67B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.60 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
685.72 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.46 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.00 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.48 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Citi lifts Beam Therapeutics stock price target to $64 - Investing.com India
Beam Therapeutics’ SWOT analysis: gene editing pioneer faces pivotal year for stock - Investing.com India
Beam Therapeutics Reports Clinical Proof-Of-Concept Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Trial - CRISPR Medicine News
Beam Therapeutics stock target holds at $37 on positive trial data - Investing.com Canada
BEAM Down Despite Positive Initial Data From Genetic Disorder Study - Nasdaq
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market - Dealbreaker
Beam Therapeutics stock target holds at $37 on positive trial data By Investing.com - Investing.com South Africa
Beam Therapeutics: Promising Phase 1 Results for BEAM-302 in AATD, Hold Rating Due to Long-term Efficacy Uncertainty - TipRanks
Beam Therapeutics (NASDAQ:BEAM) Receives “Buy” Rating from HC Wainwright - Defense World
BMO Capital maintains Outperform on Beam Therapeutics stock - MSN
In Vivo Base Editing Gets Boost with Positive Initial Data Announced by Beam Therapeutics - Genetic Engineering & Biotechnology News
Proficio Capital Partners LLC Makes New $406,000 Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Beam Therapeutics, Lennar, Redfin - TradingView
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Scotiabank to “Sector Outperform” Rating - Defense World
Beam Therapeutics’ (BEAM) Outperform Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Upgraded by Jones Trading to Buy Rating - Defense World
Scotiabank Upgrades Beam Therapeutics (BEAM) - Nasdaq
Beam Gets Important Proof Of Concept For AATD Therapy - Citeline News & Insights
Beam Therapeutics: Single-Base Editing Seems To Work - Seeking Alpha
Beam drops 9% on phase 1/2 data for genetic lung disease candidate - Seeking Alpha
JonesResearch upgrades Beam Therapeutics to Buy on de-risking data - TipRanks
Beam data ‘encouraging,’ support continuation of trial, says H.C. Wainwright - TipRanks
Promising Phase 1/2 Trial Results for Beam Therapeutics’ BEAM-302 Bolster Confidence and Support $80 Price Target - TipRanks
Scotiabank Upgrades Beam Therapeutics to Sector Outperform From Sector Perform, $40 Price Target - Marketscreener.com
Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst - TipRanks
Is Beam Therapeutics Inc. (BEAM) the Best Emerging Technology Stock to Buy Now? - Insider Monkey
Beam launches $500m financing on base-editing trial data - pharmaphorum
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga India
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition - STAT
Beam Therapeutics rises on early-stage trial results for gene editing therapy - TradingView
Beam Therapeutics Announces Positive Initial Data For BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating - TipRanks
Beam Therapeutics stock soars on positive BEAM-302 trial data - Investing.com
Beam Therapeutics Shares Surge on Promising Trial Data - TipRanks
Beam Therapeutics Reports Positive Phase 1/2 Trial Data - TipRanks
Beam Therapeutics Reprots Positive Initial Phase 1/2 Data For BEAM-302 In AATD - Nasdaq
Beam Therapeutics BEAM-302 Was Well Tolerated At All Dose Levels -March 10, 2025 at 06:11 am EDT - Marketscreener.com
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - The Manila Times
Beam Therapeutics announces ‘positive’ data from study of BEAM-302 - TipRanks
Beam Therapeutics Announces Pricing of Underwritten Offering - GlobeNewswire
Beam Therapeutics Announces Positive Initial Data for - GlobeNewswire
Breakthrough Clinical Data: Beam's Base Editor Hits Therapeutic Target - StockTitan
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Beam Therapeutics' Q4 Earnings & Revenues Beat Estimates - MSN
When (BEAM) Moves Investors should Listen - Stock Traders Daily
Cathie Wood Backs Promising Genomics Stock - Wall Street Pit
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 7.9% on Analyst Upgrade - Defense World
Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% - Yahoo Finance
Beam Therapeutics To Present At TD Cowen Health Care Conference; Webcast At 1:50 PM ET - Nasdaq
Scotiabank raises Beam Therapeutics stock target to $25 - Investing.com India
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com South Africa
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
Beam Therapeutics Inc (BEAM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Option Exercise |
7.22 |
10,000 |
72,200 |
112,968 |
| Bellon Christine | Chief Legal Officer |
Feb 14 '25 |
Sale |
34.00 |
10,000 |
340,000 |
102,968 |
5.68%
0.28%
大文字化:
|
ボリューム (24 時間):